

Mark Canney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4458525/publications.pdf>

Version: 2024-02-01

36
papers

535
citations

932766

10
h-index

676716

22
g-index

36
all docs

36
docs citations

36
times ranked

848
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparative analysis of survival of patients on dialysis and after kidney transplantation. CKJ: Clinical Kidney Journal, 2018, 11, 389-393.	1.4	127
2	Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1392-1399.	2.2	80
3	Single Agent Antihypertensive Therapy and Orthostatic Blood Pressure Behaviour in Older Adults Using Beat-to-Beat Measurements: The Irish Longitudinal Study on Ageing. PLoS ONE, 2016, 11, e0146156.	1.1	50
4	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney International, 2020, 98, 1009-1019.	2.6	35
5	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 436-447.	3.0	34
6	Mortality in Relation to Changes in a Healthy Aging Index: The Health, Aging, and Body Composition Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 726-732.	1.7	22
7	Graded Association Between Kidney Function and Impaired Orthostatic Blood Pressure Stabilization in Older Adults. Journal of the American Heart Association, 2017, 6, .	1.6	17
8	Disease-specific incident glomerulonephritis displays geographic clustering in under-served rural areas of British Columbia, Canada. Kidney International, 2019, 96, 421-428.	2.6	14
9	The Effect of Age on Performance of the Kidney Failure Risk Equation in Advanced CKD. Kidney International Reports, 2021, 6, 2993-3001.	0.4	12
10	Socioeconomic Position and Incidence of Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 367-374.	2.2	11
11	GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease. American Journal of Nephrology, 2019, 50, 105-114.	1.4	10
12	Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. JAMA Network Open, 2021, 4, e2123365.	2.8	10
13	Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study. CKJ: Clinical Kidney Journal, 2022, 15, 681-692.	1.4	10
14	The Risk of Cardiovascular Events in Individuals With Primary Glomerular Diseases. American Journal of Kidney Diseases, 2022, 80, 740-750.	2.1	10
15	ANCA in anti-GBM disease: moving beyond a one-dimensional clinical phenotype. Kidney International, 2017, 92, 544-546.	2.6	9
16	Initial and Recurrent Hyperkalemia Events in Patients With CKD in Older Adults: A Population-Based Cohort Study. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110174.	0.6	9
17	The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker. CKJ: Clinical Kidney Journal, 2018, 11, 259-264.	1.4	8
18	Maintaining the Uptake of Peritoneal Dialysis During the COVID-19 Pandemic: A Research Letter. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812098626.	0.6	8

#	ARTICLE	IF	CITATIONS
19	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. <i>CJC Open</i> , 2022, 4, 315-323.	0.7	8
20	Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults. <i>Journal of Epidemiology and Community Health</i> , 2018, 72, 287-293.	2.0	7
21	β-blockers in hemodialysis: simple questions, complicated answers. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 731-734.	1.4	7
22	Glomerular Filtration Rate-Specific Cutoffs Can Refine the Prognostic Value of Circulating Cardiac Biomarkers in Advanced Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1106-1113.	0.8	6
23	Perceptions of Multidisciplinary Renal Team Members toward Home Dialysis Therapies. <i>Kidney360</i> , 2021, 2, 1592-1599.	0.9	5
24	Management of Intermittent Hemodialysis in the Critically Ill Patient. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2023, 18, 245-255.	2.2	5
25	Finerenone: Fiddling With Hyperkalemia?. <i>American Journal of Kidney Diseases</i> , 2021, 78, 760.	2.1	3
26	Data linkage in medical science using the resource description framework: the AVERT model. <i>HRB Open Research</i> , 2018, 1, 20.	0.3	3
27	Intravenous albumin for the prevention of hemodynamic instability during sustained low-efficiency dialysis: a randomized controlled feasibility trial (The SAFER-SLED Study). <i>Annals of Intensive Care</i> , 2021, 11, 174.	2.2	3
28	COVID-19 Status, Symptom Burden, and Characteristics of Dialysis Patients Residing in Areas of Community Transmission: Research Letter. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096417.	0.6	2
29	Proteinuria and venous thromboembolism in pregnancy: a population-based cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2101-2107.	1.4	2
30	Prevalence and Impact of Chronic Debilitating Disorders. , 2017, , 151-189.		2
31	Contemporary risk prediction models in chronic kidney disease: when less is more. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 297-302.	1.0	2
32	The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	2
33	QALYs, DALYs and Now PALYs: Strengthening the Argument for Prevention of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 771-773.	3.0	1
34	Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. <i>Kidney International Reports</i> , 2021, 6, 1130-1140.	0.4	1
35	P0350THE DURATION OF PROTEINURIA REMISSION AND CLINICAL OUTCOMES IN IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
36	Reducing the risk of atrial fibrillation in ESKD: is the devil in the dialysis?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1963-1964.	0.4	0